Thermo Fisher Scientific Inc. (US), Bio-Techne (US) are Leading players in the Exosome Research Market
The exosome research market is projected to reach USD 356 million by 2028 from an estimated USD 169 million in 2023, at a CAGR of 16.0% during the forecast period. The exosome research market is mainly driven by an increasing investment in pharmaceutical R&D along with increasing interest in exosome-based procedures. Moreover, increasing demand for personalized medicine is expected to create potential growth opportunities for exosome research market growth in the forecast period.
The global exosome research market is consolidated with top players such as Thermo Fisher Scientific Inc. (US), Bio-Techne (US), QIAGEN (Germany), Lonza (Switzerland), and Danaher Corporation (US). The market players have adopted various strategies such as acquisitions, collaborations, and geographical expansions to strengthen their position in the global exosome research market.
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific Inc. is a well-established player in the exosome research market. The company has a strong brand recognition along with extensive product offerings. The company has a strong emphasis on research, as the company invested around USD 1.47 Billion in research & development in the year 2022. The company has expanded its research & development, manufacturing, sales, distribution, service, and administrative facilities in more than 80 countries. The company’s wide presence worldwide plays a key role in securing its position as a strong competitor in the exosome research market.
Bio-Techne (US)
Bio-Techne became one of the leading players in the exosome market with the acquisition of Exosome Diagnostics in 2018. The company offers a wide range of products, such as exosome diagnostic tests and instruments. This acquisition helped Bio-Techne to expand its product portfolio in the area of liquid biopsy diagnostics through the addition of new and complementary product offerings. To maintain its existing position in the market, the company prominently focuses on product launches. For instance, in January 2018, the company launched an early access version of the Shahky system. The Shahky system is the world’s first instrument specifically for exosomal protein analysis.
QIAGEN (Germany)
QIAGEN is a major provider of molecular diagnostic solutions, innovative technologies, and products for preanalytical sample preparation. The company offers consumables; automated solutions for sample collection, nucleic acid & protein handling, separation, and purification; and open and target-specific assays. QIAGEN majorly focuses on expanding its product portfolio by adopting inorganic growth strategies such as agreements with other players in the industry to strengthen its position in the market. For instance, in September 2020, the company signed a partnership agreement with Bio-Techne (US), through which QIAGEN has been granted a non-exclusive development license to exosome technology (manufactured by Bio-Techne) for the development of companion in vitro diagnostic products (CDX-IVD).
Related Reports:
Exosome Research Market by Product & Service (Kits, Reagents (Antibodies, Isolation Purification), Instruments), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
